Perspective Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Perspective Therapeutics zal naar verwachting groeien in winst en omzet met respectievelijk 2.7% en 84.5% per jaar. De winst per aandeel zal naar verwachting groeien met 5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -37.9% zijn.

Belangrijke informatie

2.7%

Groei van de winst

5.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	84.5%
Toekomstig rendement op eigen vermogen	-37.9%
Dekking van analisten	Good
Laatst bijgewerkt	21 Nov 2024

Recente toekomstige groei-updates

Recent updates

Winst- en omzetgroeiprognoses

NYSEAM:CATX - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	1	-95	-70	-84	7
12/31/2025	0	-77	-102	-80	10
12/31/2024	1	-57	-55	-41	8
9/30/2024	2	-58	-41	-1	N/A
6/30/2024	1	-52	-25	-14	N/A
3/31/2024	2	-50	-23	-13	N/A
12/31/2023	1	-37	-38	-37	N/A
9/30/2023	-1	-19	-33	-32	N/A
6/30/2023	1	-13	-25	-24	N/A
3/31/2023	3	-6	-19	-19	N/A
12/31/2022	5	-8	-11	-10	N/A
9/30/2022	10	-9	-8	-7	N/A
6/30/2022	N/A	-6	-8	-8	N/A
3/31/2022	11	-6	-6	-6	N/A
12/31/2021	11	-6	-5	-5	N/A
9/30/2021	10	-5	-5	-5	N/A
6/30/2021	10	-3	-3	-3	N/A
3/31/2021	10	-4	-3	-3	N/A
12/31/2020	10	-3	-3	-3	N/A
9/30/2020	10	-3	-4	-3	N/A
6/30/2020	10	-3	-4	-4	N/A
3/31/2020	9	-3	-4	-4	N/A
12/31/2019	8	-4	-5	-4	N/A
9/30/2019	8	-4	-5	-4	N/A
6/30/2019	7	-5	-5	-5	N/A
3/31/2019	7	-6	-6	-6	N/A
12/31/2018	7	-7	-6	-5	N/A
9/30/2018	6	-7	-6	-6	N/A
6/30/2018	6	-7	N/A	-6	N/A
3/31/2018	6	-6	N/A	-5	N/A
12/31/2017	5	-6	N/A	-6	N/A
9/30/2017	5	-6	N/A	-6	N/A
6/30/2017	5	-6	N/A	-6	N/A
3/31/2017	5	-6	N/A	-6	N/A
12/31/2016	4	-5	N/A	-5	N/A
9/30/2016	5	-5	N/A	-4	N/A
6/30/2016	5	-5	N/A	-4	N/A
3/31/2016	5	-5	N/A	-3	N/A
12/31/2015	5	-4	N/A	-4	N/A
9/30/2015	5	-4	N/A	-3	N/A
6/30/2015	5	-4	N/A	-4	N/A
3/31/2015	4	-4	N/A	-4	N/A
12/31/2014	4	-5	N/A	-3	N/A
9/30/2014	4	-5	N/A	-3	N/A
6/30/2014	4	-7	N/A	-3	N/A
3/31/2014	4	-6	N/A	-3	N/A
12/31/2013	5	-5	N/A	-3	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat CATX de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat CATX de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat CATX de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van CATX ( 84.5% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van CATX ( 84.5% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat CATX binnen 3 jaar verliesgevend zal zijn.

Perspective Therapeutics Toekomstige groei

Future criteriumcontroles 2/6

Belangrijke informatie

Recente toekomstige groei-updates

Consensus revenue estimates increase by 51%, EPS downgraded

No longer forecast to breakeven

Forecast to breakeven in 2026

Recent updates

Perspective Therapeutics, Inc. Announces Initial Results from its Ongoing Phase 1/2a Clinical Trial of [212Pb] VMT-a-Net

New minor risk - Share price stability

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Revenue size

Perspective Therapeutics, Inc. to Report Q3, 2024 Results on Nov 12, 2024

Perspective Therapeutics Begins Shipping Investigational Products from Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey

Perspective Therapeutics to Advance Investigation of Potential First-In-Class Radiopharmaceutical Therapy (212Pb)Vmt01 Based on Data Presented At the 21St International Congress of the Society for Melanoma Research

Perspective Therapeutics Grants Fast Track Designation for VMT01 for the Diagnosis and Treatment of MC1R-Positive Melanoma

Consensus revenue estimates increase by 51%, EPS downgraded

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $49.868808 million.

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Perspective Therapeutics, Inc. to Report Q2, 2024 Results on Aug 12, 2024

CFO & Co-Principal Financial Officer recently bought US$177k worth of stock

CEO & Director recently bought US$117k worth of stock

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $79.998535 million.

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Perspective Therapeutics, Inc. to Report Q1, 2024 Results on May 15, 2024

New minor risk - Profitability

No longer forecast to breakeven

Full year 2023 earnings released: US$0.14 loss per share (vs US$0.10 loss in FY 2022)

Perspective Therapeutics, Inc., Annual General Meeting, May 31, 2024

Perspective Therapeutics, Inc. announced that it has received $87.409482 million in funding from Lantheus Holdings, Inc.

Perspective Therapeutics, Inc. announced that it expects to receive $87.409482 million in funding from Lantheus Holdings, Inc. and other investors

Perspective Therapeutics, Inc. (NYSEAM:CATX) completed the acquisition of Radiopharmaceutical Manufacturing Facility in Somerset, New Jersey from Progenics Pharmaceuticals, Inc.

Perspective Therapeutics, Inc. Introduces Pre-Targeting Theranostic Technology Platform

Chief Medical Officer recently bought US$140k worth of stock

Forecast to breakeven in 2026

Perspective Therapeutics, Inc. announced that it has received $20.846671 million in funding from Lantheus Alpha Therapy, LLC

Perspective Therapeutics, Inc. announced that it expects to receive $20.8 million in funding

Perspective Therapeutics, Inc. has completed a Follow-on Equity Offering.

Chief Medical Officer recently bought US$189k worth of stock

Perspective Therapeutics, Inc. Announces First Patient Dosed in A Phase 1 Study Of212pb)Vmt-A-Net to Treat Refractory or Relapsed Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces First Ever Human SPECT Imaging of Pb-212 with VMT-a-NET by Clinical Collaborators in Germany

Perspective Therapeutics, Inc. Announces Publication of Four Preclinical Studies in Peer-Reviewed Journals

New major risk - Financial position

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Perspective Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Third quarter 2023 earnings: EPS in line with expectations, revenues disappoint

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2A Study of [(212)Pb VMT-a-Net for Treatment of Advanced SSTR2-Positive Neuroendocrine Tumors

Perspective Therapeutics, Inc. Announces Two Upcoming Investigator-Initiated Trials

Perspective Therapeutics, Inc. Announces Presentation of Positive Early Clinical Data for VMT-a-NET at 36th Annual Congress of European Association of Nuclear Medicine

Perspective Therapeutics, Inc. Presents Positive Preclinical Alpha Particle Therapy Data at the World Molecular Imaging Congress 2023 and the 36th Annual Congress of the European Association of Nuclear Medicine

Perspective Therapeutics, Inc., Annual General Meeting, Oct 06, 2023

New major risk - Financial position

Perspective Therapeutics, Inc. Announces First Patient Dosed in Phase 1/2a Dose Escalation Trial of VMT01 of its Targeted Alpha-Particle Therapy (TAT), for Treatment of MC1R-positive Metastatic Melanoma

Second quarter 2023 earnings released

Perspective Therapeutics, Inc. Announces Termination of Jennifer Streeter as Chief Operating Officer

Less than half of directors are independent

Perspective Therapeutics, Inc.'s Cesium-131 Features at the American Brachytherapy Society's Annual Conference

Perspective Therapeutics, Inc. Initiates Phase 1/2a Clinical Trials for Two Targeted Alpha Therapy Oncology Product Candidates

Less than half of directors are independent

Perspective Therapeutics, Inc. Announces Changes to the Board of Directors

First quarter 2023 earnings released: US$0.002 loss per share (vs US$0.009 loss in 1Q 2022)

Chairperson of the Board exercised options to buy US$129k worth of stock.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Isoray, Inc. Announces Termination of William Cavanagh III as Chief Research and Development Officer

Isoray, Inc. Announces Executive Changes

Isoray, Inc., Annual General Meeting, Jan 12, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Insufficient new directors

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven